Chul‐Woong Chung

1.3k citations

20 papers · 1.1k indexed · 1 hit paper · h-index 12

Co-authors: Yong‐Keun Jung Yong‐Soon Cho Nam‐Chul Ha Byung‐Ha Oh Hyun‐Ju Kim Jong‐Ik Hwang Sejeong Shin Byungje Sung
Topics: HER2/EGFR in Cancer Research (7 papers)Monoclonal and Polyclonal Antibodies Research (7 papers)Cell death mechanisms and regulation (6 papers)
Cited by: Molecular Biology Oncology Cell Biology
Journals: Angewandte Chemie International EditionSHILAP Revista de lepidopterologíaThe Journal of Cell Biology
Partner nations: South Korea United States Japan

In The Last Decade

Chul‐Woong Chung

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and -7

2001 587 citations Sejeong Shin, Byungje Sung et al. Biochemistry profile →

Peers

Countries citing papers authored by Chul‐Woong Chung

Since Specialization

Citations

This map shows the geographic impact of Chul‐Woong Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chul‐Woong Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chul‐Woong Chung more than expected).

Fields of papers citing papers by Chul‐Woong Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chul‐Woong Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chul‐Woong Chung. The network helps show where Chul‐Woong Chung may publish in the future.

Co-authorship network of co-authors of Chul‐Woong Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Chul‐Woong Chung. A scholar is included among the top collaborators of Chul‐Woong Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chul‐Woong Chung. Chul‐Woong Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers 2024 ·Cancer Research ·Daniel P. Fitzgerald,(unknown),(unknown),Shannon M. Kahan,(unknown),(unknown),Kwang Hwa Jung,Hwanhee Oh,(unknown),(unknown),Shanmugam Panneer Selvam,Dallas B. Flies,Chul‐Woong Chung,Sol Langermann	0
2	1051 LNCB74 is a B7-H4 targeting antibody-drug-conjugate with a β-glucuronide linker-MMAE payload system to enhance the therapeutic index in B7-H4 expressing cancers 2024 ·Regular and Young Investigator Award Abstracts ·Shannon M. Kahan,Daniel P. Fitzgerald,(unknown),Ngoc‐Duc Doan,(unknown),(unknown),(unknown),(unknown),Hwanhee Oh,(unknown),(unknown),Shanmugam Panneer Selvam,Dallas B. Flies,(unknown),Chul‐Woong Chung,Sol Langermann	0
3	897 AST-301, a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model 2023 ·SHILAP Revista de lepidopterología ·Jin-Ho Kang,(unknown),Jee Hyun Choi,(unknown),(unknown),Minah Kim,(unknown),Yun‐Hee Park,Soyeon Lim,Chul‐Woong Chung,Jin Kyeong Choi,(unknown),(unknown)	2
4	Abstract 702: A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy 2023 ·Cancer Research ·(unknown),Juhyeon Kim,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Chul‐Woong Chung	2
5	Abstract 1753: IKS014, a HER2-targeting antibody drug conjugate incorporating novel bioconjugation and tumor-selective linker technology with improved in vivo efficacy and tolerability 2022 ·Cancer Research ·Jutta Deckert,Jenny Thirlway,Yun‐Hee Park,Ho Young Song,Chul‐Woong Chung,Xuesong Wang,Zhenshan Zhang,Robert J. Lutz	5
6	Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-selective anti-TROP2 monoclonal antibody, a proprietary site-directed conjugation technology and plasma-stable tumor-selective linker chemistry 2022 ·Cancer Research ·Hye Jung Kim,Emanuela Guerra,(unknown),(unknown),(unknown),Byeongjun Yu,(unknown),Saverio Alberti,Chul‐Woong Chung,Chang-Sik Park	6
7	IKS03, a Next Generation CD19-Targeted Antibody Drug Conjugate, Shows Potent Activity in Preclinical Models of Aggressive B-Cell Lymphomas 2022 ·Blood ·Jutta Deckert,Jenny Thirlway,(unknown),(unknown),Yun‐Hee Park,(unknown),(unknown),Ho Young Song,Chul‐Woong Chung,Robert J. Lutz	1
8	An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers 2021 ·Advanced Science ·(unknown),Yun‐Hee Park,Seok Soon Park,Eun Jin Ju,Jin Hyoung Park,Eun Jung Ko,(unknown),Sang‐Yeob Kim,Chul‐Woong Chung,Ho Young Song,Se Jin Jang,Seong‐Yun Jeong,Si Yeol Song,Eun Kyung Choi	29
9	A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening 2018 ·Biochemical and Biophysical Research Communications ·Young Hun Kim,Minsung Kim,(unknown),Ji Eun Kim,Heung Kyoung Lee,Jung‐Nyoung Heo,Chong Ock Lee,(unknown),Kwan‐Young Jung,Chang‐Soo Yun,(unknown),Hye Kyung Chang,Chul‐Woong Chung,Suhkneung Pyo,Sang Un Choi,Chi Hoon Park	12
10	Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein–Drug Conjugates for Targeted Therapy 2015 ·Angewandte Chemie International Edition ·Joong‐jae Lee,Hyo‐Jung Choi,Misun Yun,(unknown),Jieun Jung,(unknown),(unknown),(unknown),Hyun‐Soo Cho,Jung‐Joon Min,Chul‐Woong Chung,Hak‐Sung Kim	73
11	Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein–Drug Conjugates for Targeted Therapy 2015 ·Angewandte Chemie ·Joong‐jae Lee,Hyo‐Jung Choi,Misun Yun,(unknown),Jieun Jung,(unknown),(unknown),(unknown),Hyun‐Soo Cho,Jung‐Joon Min,Chul‐Woong Chung,Hak‐Sung Kim	8
12	E2-25K/Hip-2 regulates caspase-12 in ER stress–mediated Aβ neurotoxicity 2008 ·The Journal of Cell Biology ·Sungmin Song,Huikyong Lee,Tae‐In Kam,(unknown),Joo‐Yong Lee,(unknown),Sang Mi Shim,Soo Jung Seo,Young‐Yun Kong,Toshiyuki Nakagawa,Chul‐Woong Chung,Deog-Young Choi,Hammou Oubrahim,Yong‐Keun Jung	79
13	Role of FLASH in caspase-8-mediated activation of NF-κB: dominant-negative function of FLASH mutant in NF-κB signaling pathway 2004 ·Oncogene ·Joon-Il Jun,Chul‐Woong Chung,Ho‐June Lee,(unknown),Kee Nyung Lee,Nam-Soon Kim,Yong‐Sung Kim,Hyang‐Sook Yoo,Tae‐Ho Lee,Eunhee Kim,Yong‐Keun Jung	24
14	Essential Role of E2-25K/Hip-2 in Mediating Amyloid-β Neurotoxicity 2003 ·Molecular Cell ·Sungmin Song,Soyoung Kim,Yeon‐Mi Hong,Dong‐Gyu Jo,Joo‐Yong Lee,Sang Mi Shim,Chul‐Woong Chung,Soo Jung Seo,Yung Joon Yoo,Jae‐Young Koh,Min Chul Lee,Allan J. Yates,Hidenori Ichijo,Yong‐Keun Jung	135
15	Atypical role of proximal caspase-8 in truncated Tau-induced neurite regression and neuronal cell death 2003 ·Neurobiology of Disease ·Chul‐Woong Chung,Yeon‐Mi Hong,Sungmin Song,Ha‐Na Woo,(unknown),Troy T. Rohn,Yong‐Keun Jung	17
16	Caspase cleavage product lacking amino‐terminus of IκBα sensitizes resistant cells to TNF‐α and TRAIL‐induced apoptosis* 2002 ·Journal of Cellular Biochemistry ·Ki Woo Kim,(unknown),Chul‐Woong Chung,Dong‐Gyu Jo,(unknown),(unknown),(unknown),Ha‐Na Woo,Yong‐Keun Jung	22
17	POTENTIATION OF FAS- AND TRAIL-MEDIATED APOPTOSIS BY IFN-γ IN A549 LUNG EPITHELIAL CELLS: ENHANCEMENT OF CASPASE-8 EXPRESSION THROUGH IFN-RESPONSE ELEMENT 2002 ·Cytokine ·(unknown),(unknown),(unknown),Chul‐Woong Chung,(unknown),(unknown),Yong‐Keun Jung	39
18	An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and -7breakdown → 2001 ·Biochemistry ·Sejeong Shin,Byungje Sung,Yong‐Soon Cho,Hyun‐Ju Kim,Nam‐Chul Ha,Jong‐Ik Hwang,Chul‐Woong Chung,Yong‐Keun Jung,Byung‐Ha Oh	587
19	Pro‐apoptotic function of calsenilin/DREAM/KChIP3 2001 ·The FASEB Journal ·Dong‐Gyu Jo,(unknown),Yun‐Hee Choi,(unknown),(unknown),Ha‐Na Woo,Chul‐Woong Chung,Yong‐Keun Jung	65
20	Reconstitution of Caspase-8 Sensitizes JB6 Cells to TRAIL 2000 ·Biochemical and Biophysical Research Communications ·(unknown),Chul‐Woong Chung,Ha‐Na Woo,(unknown),(unknown),Yong‐Keun Jung	18

About Chul‐Woong Chung

Chul‐Woong Chung is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 20 papers that have together received 1.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cell death mechanisms and regulation (6 papers). The work is most often cited by research in Molecular Biology (829 citations), Oncology (306 citations) and Cell Biology (170 citations). Chul‐Woong Chung has collaborated with scholars based in South Korea, United States and Japan. Frequent co-authors include Yong‐Keun Jung, Yong‐Soon Cho, Nam‐Chul Ha, Byung‐Ha Oh, Hyun‐Ju Kim, Jong‐Ik Hwang, Sejeong Shin, Byungje Sung, Dong‐Gyu Jo and Sungmin Song. Their work appears in journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and The Journal of Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact